Completed PHASE4 INTERVENTIONAL 2-arm NCT00134160

OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study

The Study Comparing the Incidence of Cardiovascular Events Between High-dose ARB Monotherapy and Combination Therapy With ARB and Calcium Channel Blocker in Japanese Elderly Hypertensive Patients at High Cardiovascular Risk

Sponsor: Japan Heart Foundation

Conditions Cardiovascular Diseases Hypertension

Interventions Calcium channel blockers (amlodipine, azelnidipine) Olmesartan medoxomil

Updated 5 times since 2017 Last updated: Oct 3, 2010 Started: Aug 31, 2005 Primary completion: May 31, 2010 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Cardiovascular Diseases and Hypertension and is currently completed. Japan Heart Foundation leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Japan Heart Foundation
OSCAR Study

Data source: OSCAR Study

For direct contact, visit the study record on ClinicalTrials.gov .

OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study

Status Flow

Change History

Eligibility Summary

Contact Information

Study Locations

Related Trials